Pharmacists Mike Boivin, John Papastergiou and Hitesh Pandya kicked things off with a ground-level view of what happens at the dispensary counter with plan members. In one case, a patient had been using samples for an antidepressant from his physician. When he learned his plan did not cover the drug, he paid for the medication […]
On-site wellness clinics can be an effective entry point for pharmacy services. Based on its data from such programs in the workplace, MHCSI Managed Health Care Services Inc. has found that about a third of plan members are at risk of chronic disease and a third are at very high risk, noted Leanne MacFarlane, MHCSI’s […]
Pharmacist Mike Cavanagh presented on behalf of the Pharmacy Health Insurance Steering Coalition (PHISC), a joint initiative by the Canadian Life and Health Insurance Association, the Neighbourhood Pharmacies Association of Canada and the Canadian Pharmacists Association. PHISC is putting the finishing touches on a package that explains the pharmacy services that could be covered by […]
Benefits Canada’s 2015 Pharmacy Solutions In Drug Plan management wrapped up with a five-member panel that considered the future of drug benefits. As specialty drugs continue to grow their share of the market, it may be safe to assume that “new drugs aren’t simply going to be added to formularies, whether they’re specialty or otherwise,” […]
Plan sponsors miscalculate how many of their employees have chronic diseases, which suggests they may also underestimate these diseases’ impact over time.
Providers and pharmacies come together around mutual goals, bringing new opportunities for benefits plan sponsors.
To protect the sustainability of private drug plans, non-traditional alliances need to become the norm.
Plan sponsors and plan members have become remarkably open to the notion of the workplace supporting personal health, according to the 16th annual Sanofi Canada Healthcare Survey.
Growing drug plan costs are putting pressure on benefits plan sponsors to move to managed formularies—but industry stakeholders must first work together to change the drug evaluation process to ensure coverage decisions deliver the best value.